Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria

Acta Tropica

Volumn 127, Issue 3, 2013, Pages 165-173

  Kuntworbe, N ^a   Ofori, M ^b   Addo, P ^b   Tingle, M ^a   Al Kassas, R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b University of Ghana   (Ghana)

Author keywords

Chemosuppression; Cryptolepine hydrochloride; Nanoparticles; Pharmacokinetics

Indexed keywords

ANTIMALARIAL AGENT; CRYPTOLEPINE DERIVATIVE; CRYPTOLEPINE HYDROCHLORIDE; GELATIN; NANOPARTICLE; UNCLASSIFIED DRUG;

CONCENTRATION (COMPOSITION); DISEASE TREATMENT; DRUG PRESCRIBING; MALARIA; NANOTECHNOLOGY; PARASITIC DISEASE; PLASMA; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SMEAR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; GIEMSA STAIN; MALARIA; MALE; MICROSCOPY; NONHUMAN; PARASITE LOAD; PARASITEMIA; PLASMODIUM BERGHEI INFECTION; RAT; SINGLE DRUG DOSE;

CHEMOSUPPRESSION; CRYPTOLEPINE HYDROCHLORIDE; NANOPARTICLES; PHARMACOKINETICS;

ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; BRAIN CHEMISTRY; DRUG ADMINISTRATION ROUTES; GELATIN; INDOLE ALKALOIDS; KIDNEY; LIVER; LUNG; MALARIA; MALE; MOLECULAR STRUCTURE; MYOCARDIUM; NANOSTRUCTURES; QUINOLINES; RATS; RATS, WISTAR; SPLEEN;

ANIMALIA; RATTUS NORVEGICUS;

EID: 84878379360     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.04.010     Document Type: Article

References (26)

1. Arzel E., Rocca P., Grellier P., Labaeid M., Frappier F., Gueritte F., Gaspard C., Marsais F., Godard A., Queguiner G. New synthesis of benzo-δ-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of δ-carbolines, benzo-δ-carbolines, and cryptolepines. J. Med. Chem. 2001, 44:949-960.
2. Bamgbose S.O., Noamesi B.K. Studies on cryptolepine. II. Inhibition of carrageenan induced oedema by cryptolepine. Planta Med. 1981, 41(392):396.
3. Bierer D.E., Fort D.M., Mendez C.D., Luo J., Imbach P.A., Dubenko L.G., Jolad S.D., Gerber R.E., Litvak J., Lu Q., Zhang P., Reed M.J., Waldeck N., Bruening R.C., Noamesi B.K., Hector R.F., Carlson T.J., King S.R. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. J. Med. Chem. 1998, 41:894-901.
4. Boakye-Yiadom K., Heman-Ackah S.M. Cryptolepine hydrochloride effect on Staphylococcus aureus. J. Pharm. Sci. 1979, 68:1510-1514.
5. Cimanga K., De Bruyne T., Pieters L., Vlietinck A.J., Turger C.A. In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepissanguinolenta. J. Nat. Prod. 1997, 60:688-691.
6. Egan T.J., Hunter R., Kaschula C.H., Marques H.M., Misplon A., Walden J. Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of β-hematin formation, and antiplasmodial activity. J. Med. Chem. 2000, 43:283-291.
7. Eisenstein M. Drug development: holding out for reinforcements. Nature 2012, 484:S16-S18.
8. Greenwood B., Armstrong J. Comparison of two simple methods for determining malaria parasite density. Trans. R. Soc. Trop. Med. Hyg. 1991, 85:186-188.
9. Grellier P., Ramiaramanana L., Millerioux V., Deharo E., Schrével J., Frappier F., Trigalo F., Bodo B., Pousset J. Antimalarial activity of cryptolepine and isocryptolepine, alkaloids isolated from Cryptolepis sanguinolenta. Phytother. Res. 1996, 10:317-321.
10. Haas S.E., Bettoni C.C., de Oliveira L.K., Guterres S.S., Dalla Costa T. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int. J. Antimicrob. Agents 2009, 34:156-161.
11. Hawley S.R., Bray P.G., O'Neill P.M., Park B.K., Ward S.A. The role of drug accumulation in 4-aminoquinoline antimalarial potency: The influence of structural substitution and physicochemical properties. Biochem. Pharmacol. 1996, 52:723-733.
12. Kirby G.C., Paine A., Warhurst D.C., Moamese B.K., Philipson J.D. In vitro and in vivo antimalarial activity of cryptolepine, a plant-derived indoloquinoline. Phytother. Res. 1995, 9:359-363.
13. Kuntworbe N., Al-Kassas R. Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria. AAPS PharmSciTech 2012, 13:1-14.
14. Kuntworbe N., Martini N., Brimble M., Alany G.R., Al-Kassas R. Isolation and development of an HPLC method for the detection and quantification of cryptolepine and its application in the determination of the total cryptolepine content in the root powder of Cryptolepis sanguinolenta. Pharmacol. Pharm. 2012, 3:263-270.
15. McCurrie J., Albalawi S., Wright C., Kuntworbe N. Investigation of the absorption and vascular effects of the indoloquinoline alkaloid, cryptolepine. British Pharmaceutical Conference, J. Pharm. Pharmacol. 2009, A67-A68.
16. Noamesi B.K., Larsson B.S., Laryea D.L., Ullberg S. Whole-body autoradiographic study on the distribution of 3H-cryptolepine in mice. Arch. Int. Pharmacodyn. Ther. 1991, 313:5-14.
17. Olajide O.A., Ajayi A.M., Wright C.W. Anti-inflammatory properties ofcryptolepine. Phytother. Res. 2009, 23:1421-1425.
18. Onyeibor O., Croft S.L., Dodson H.I., Feiz-Haddad M., Kendrick H., Millington N.J., Parapini S., Phillips R.M., Seville S., Shnyder S.D., Taramelli D., Wright C.W. Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. J. Med. Chem. 2005, 48:2701-2709.
19. 2+ channels. Eur. J. Pharmacol. 1995, 285:1-9.
20. Peters W. The chemotherapy of rodent malaria. XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann. Trop. Med. Parasitol. 1975, 69:155-171.
21. Salako Q., Ablordeppey S.Y., Dwuma-Badu D., Thornback J.R. Radioiodination and preliminary in vivo investigation of the alkaloid cryptolepine. Int. J. Appl. Radiat. Isot. 1985, 36:1003-1004.
22. Santos-Magalhães N.S., Mosqueira V.C. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 2010, 62:560-575.
23. Sawer I.K., Berry M.I., Ford J.L. The killing effect of cryptolepine on Staphylococcus aureus. Lett. Appl. Microbiol. 2005, 40:24-29.
24. Singh M., Singh M.P., Ablordeppey S. In vitro studies with liposomal cryptolepine. Drug Dev. Ind. Pharm. 1996, 22:377-381.
25. WHO World Malaria Report 2011.
26. Wright C.W., Addae-Kyereme J., Breen A.G., Brown J.E., Cox M.F., Croft S.L., Gokcek K.Y., Kendrick H., Phillips R.M., Pollet P.L. Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. J. Med. Chem. 2001, 44:3187-3194.